JP6983075B2 - 極性の組換え延長部を有するインスリン - Google Patents

極性の組換え延長部を有するインスリン Download PDF

Info

Publication number
JP6983075B2
JP6983075B2 JP2017562721A JP2017562721A JP6983075B2 JP 6983075 B2 JP6983075 B2 JP 6983075B2 JP 2017562721 A JP2017562721 A JP 2017562721A JP 2017562721 A JP2017562721 A JP 2017562721A JP 6983075 B2 JP6983075 B2 JP 6983075B2
Authority
JP
Japan
Prior art keywords
human insulin
insulin
desb30 human
desb30
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017562721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527288A (ja
JP2018527288A5 (enExample
Inventor
トマス・バアウロム・ケルスン
トマス・ホウ−イェンセン
ティネ・ニガール・ヴィンター
フランティセク・フバレク
イングリッド・ペテルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2018527288A publication Critical patent/JP2018527288A/ja
Publication of JP2018527288A5 publication Critical patent/JP2018527288A5/ja
Priority to JP2021070977A priority Critical patent/JP2021119156A/ja
Application granted granted Critical
Publication of JP6983075B2 publication Critical patent/JP6983075B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2017562721A 2015-06-02 2016-06-02 極性の組換え延長部を有するインスリン Expired - Fee Related JP6983075B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021070977A JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15170337.8 2015-06-02
EP15170337 2015-06-02
EP15176207 2015-07-10
EP15176207.7 2015-07-10
PCT/EP2016/062514 WO2016193380A1 (en) 2015-06-02 2016-06-02 Insulins with polar recombinant extensions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021070977A Division JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Publications (3)

Publication Number Publication Date
JP2018527288A JP2018527288A (ja) 2018-09-20
JP2018527288A5 JP2018527288A5 (enExample) 2019-05-09
JP6983075B2 true JP6983075B2 (ja) 2021-12-17

Family

ID=56098249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562721A Expired - Fee Related JP6983075B2 (ja) 2015-06-02 2016-06-02 極性の組換え延長部を有するインスリン
JP2021070977A Withdrawn JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021070977A Withdrawn JP2021119156A (ja) 2015-06-02 2021-04-20 極性の組換え延長部を有するインスリン

Country Status (6)

Country Link
US (1) US11208452B2 (enExample)
EP (1) EP3303380B1 (enExample)
JP (2) JP6983075B2 (enExample)
CN (1) CN107743494B (enExample)
ES (1) ES2784603T3 (enExample)
WO (1) WO2016193380A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CN112312922B (zh) * 2018-06-21 2025-04-11 诺和诺德股份有限公司 用于治疗肥胖症的新型化合物
HUE062719T2 (hu) 2018-06-29 2023-11-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20210393745A1 (en) 2018-10-10 2021-12-23 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
KR102865175B1 (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
DE102020110543A1 (de) 2020-04-17 2021-10-21 Bayerische Motoren Werke Aktiengesellschaft Energiespeichereinrichtung, Kraftfahrzeug und Kühlplattenanordnung
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP3915571A1 (en) * 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
CA3193453A1 (en) * 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN115716877B (zh) * 2022-07-04 2023-09-01 北京惠之衡生物科技有限公司 一种表达glp-1和胰岛素缀合物多肽的重组工程菌
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286509C (enExample)
DE257197C (enExample)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
DD257197A1 (de) 1987-01-28 1988-06-08 Univ Dresden Tech Verfahren zur herstellung von immobilisierten, in ihrer biologischen aktivitaet stabilisierten und in ihren pharmakologischen eigenschaften modifizierten insulinpraeparationen
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DD286509A5 (de) 1989-06-30 1991-01-31 Veb Berlin-Chemie,De Verfahren zur herstellung von aktivitaetsstabilisierten, wirkungsverlaengerten rektal applizierbaren insulinpraeparationen
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
ATE317443T1 (de) 1996-12-20 2006-02-15 Novo Nordisk As N-terminal verlängerte proteine exprimiert in hefe
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
JP2004524020A (ja) 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
AU2002341215A1 (en) 2001-11-12 2003-05-26 University Of Wales College Of Medicine Growth hormone variations in humans and their uses
GB2384001B (en) 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CN101111516B (zh) * 2005-01-25 2013-02-27 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
CA2595695A1 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Biologically active protein conjugates comprising (nn[s/t]) peptide repeats and having increased plasma half-life
US20090036353A1 (en) 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
MX2007009906A (es) 2005-02-16 2007-09-25 Novo Nordisk As Derivados de agentes insulinotropicos conjugados con polimeros ramificados estructuralmente bien definidos.
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8492129B2 (en) 2005-12-12 2013-07-23 Innova Biosciences, Ltd. Production of conjugates
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2008052108A2 (en) 2006-10-26 2008-05-02 Centocor Ortho Biotech Inc. Methods for use in human-adapting monoclonal antibodies
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
CN106822891A (zh) 2008-06-20 2017-06-13 诺华公司 具有降低的聚集的免疫球蛋白
WO2010001196A1 (en) 2008-07-02 2010-01-07 Koninklijke Philips Electronics N.V. V-spring configuration and end attachment assemblies therefor for use in a personal care appliance
EP2300501B1 (en) 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
EP2494061B1 (en) 2009-10-29 2017-01-25 Janssen Biotech, Inc. Antibody glycosylation variants
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
DK2571510T3 (en) 2010-05-21 2018-11-19 Xl Protein Gmbh BIOSYNTHETIC PROLIN / ALANIN-RANDOM COIL POLYPEPTIDES AND THEIR APPLICATIONS
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
EP2694528A1 (en) 2011-04-05 2014-02-12 Martin-Protean, LLC Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
CN106068274A (zh) 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
US11279771B2 (en) 2014-09-17 2022-03-22 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
WO2016133372A2 (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
ES2907651T3 (es) 2015-08-14 2022-04-25 Remegen Biosciences Inc Enlazadores covalentes en conjugados de anticuerpo-fármaco y métodos para obtener y usar los mismos
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート

Also Published As

Publication number Publication date
EP3303380A1 (en) 2018-04-11
ES2784603T3 (es) 2020-09-29
CN107743494A (zh) 2018-02-27
US11208452B2 (en) 2021-12-28
CN107743494B (zh) 2022-04-29
JP2021119156A (ja) 2021-08-12
US20180291076A1 (en) 2018-10-11
WO2016193380A1 (en) 2016-12-08
JP2018527288A (ja) 2018-09-20
EP3303380B1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
JP2021119156A (ja) 極性の組換え延長部を有するインスリン
RU2684456C2 (ru) Новые производные инсулина и их применение в медицине
JP2021177779A (ja) 新規インスリン誘導体及びその医学的使用
US20090069216A1 (en) Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
KR20090071561A (ko) 프로테아제 내성 인슐린 유사체
JPH11502110A (ja) インスリン誘導体
US20200283493A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof
EP3642338A1 (en) Fusion protein with half-life extending polypeptide
KR20200038502A (ko) 신규한 아실화 인슐린 유사체 및 이의 용도
JP6995284B2 (ja) 新規インスリン類似体およびそれらの使用
US7078485B2 (en) N-terminal modified recombinant human endostatin and its production
JP6013330B2 (ja) 追加のジスルフィド結合を含有するヒトインスリン
JP2018531899A (ja) 新規インスリン誘導体及びその医学的使用
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ）
EP1654283A1 (en) Improved method of purifying tfpi and tfpi analogs
JP2022533066A (ja) ポリペプチド誘導体およびその調製方法
Liang et al. Purification and Activity Evaluation of a Novel Thrombopoietin Mimetic Peptide
EA049440B1 (ru) Новые аналоги инсулина и варианты их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210420

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210420

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210427

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211122

R150 Certificate of patent or registration of utility model

Ref document number: 6983075

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees